Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years
Key facts
- Who runs it
- Centers for Disease Control and Prevention
- Where
- Houston, Salt Lake City, Tallahassee, and Tucson, United StatesSee the 4 sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 3,988 people enrolled
- Started
- 13 Sept 2022
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Fluzone Quadrivalent
- Flublok Quadrivalent
- Record updated
- 30 July 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Aged 18-64 years
- Comfortable reading and responding to text messages or emails sent in either English, Spanish, or Chinese
- Currently enrolled as a student in a college or graduate degree program AND attending in-person classes with other students; OR Currently employed as a frontline worker defined as an occupation that cannot be done from home or alone AND have direct face-to-face contact, defined as being within 6 feet, or about two arms' lengths, with co-workers, patients or the public as part of full-time (at least 20 hours per week) job responsibilities
- Have daily access to the internet and a mobile phone that can send and receive text messages
- Plan to continue to live/work in the study area through May 2023 (if trial season 1) or May 2024 (if trial season 2). For students in college or graduate degree programs, this is defined as living/working in the area excluding brief absences during school vacation periods
Who cannot take part
- Previous hypersensitivity reaction to the study vaccines as reported by the subject
- Has already received current year influenza vaccine on our after July 1, 2022 as reported by the subject
- Lives with another person who is already enrolled in this study as reported by the subject
Where in United States
- Baylor College of MedicineHouston, United States
- University of UtahSalt Lake City, United States
- Florida A&M UniversityTallahassee, United States
- University of ArizonaTucson, United States
About the trial
What the trial wants to find out
This randomized, active comparator trial will compare the clinical efficacy of recombinant influenza vaccine (RIV) to standard-dose egg-based inactivated influenza vaccine (SD IIV) among adults aged 18-64 years. The primary study hypothesis is that the clinical efficacy of RIV is superior to that of SD IIV to prevent and attenuate influenza-like illness (ILI)-associated influenza virus infection. Relative efficacy will be assessed by comparing rates of ILI-associated reverse transcription polymerase chain reaction (RT-PCR)-confirmed influenza virus infection and measures of infection and illness attenuation among participants who receive RIV versus SD IIV. A secondary hypothesis is that humoral and cell-mediated immune responses to RIV are superior to responses to SD IIV. Relative immunogenicity will be assessed by comparing markers of humoral and cell-mediated immune responses post-vaccination among a subset of participants who receive RIV versus SD IIV.
The 2 groups in the trial
- Recombinant Influenza Vaccine (RIV)Existing treatment, for comparison
recombinant vaccine Flublok® Quadrivalent
Treatment: Flublok Quadrivalent
- Standard-Dose Inactivate Influenza Vaccine (SD IIV)Existing treatment, for comparison
egg-based vaccines Fluzone® Quadrivalent or Fluarix® Quadrivalent at approximately 28 days after receipt of the 2018-19 and 2019-20 vaccines
Treatment: Fluzone Quadrivalent
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Participant- and Investigator-Blinded Trial to Compare the Clinical Efficacy of Recombinant Influenza Vaccine to Standard Dose Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years in the United States
- Publications
- Record updated
- 30 July 2026